More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Over the next week, we'll be looking back at some of our favorite Goats and Soda stories to see "whatever happened to ..." In July 2024, we published a story with the headline: "One of the 7 people ...

A University of Massachusetts Amherst public health researcher has received four grants totaling $17.9 million from the ...

WHO has sounded alarm over a sharp spike in HIV cases in the Philippines, Fiji and Papua New Guinea, urging urgent prevention ...